• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

P-012 Thrombectomy aspiration post-market study in acute stroke: the TAPAS study
ConclusionThe Q Aspiration Catheter is a novel technology that showed comparable deliverability and revascularization rates as other commercially available catheters with no safety concerns. More prospective clinical data is needed to fully assess the Q Aspiration Catheter.AbbreviationsAIS (acute ischemic stroke), MT (mechanical thrombectomy), ASPECTs (Alberta Stroke Program Early CT Score), mTICI (modified TICI score), NIHSS (National Institute of Health Stroke Scale), mRS (modified Rankin Scale), ENT (embolization to a new territory), sICH (symptomatic intracranial hemorrhage)Disclosures F. Ballenilla: 2; C; MIVI Neurosc...
Source: Journal of NeuroInterventional Surgery - July 26, 2021 Category: Neurosurgery Authors: Ballenilla, F., Espinosa, M., Zamarro, J., Masso, J., Garmendia, E., Pumar, J., Larrea, J., Mosqueira, A. Tags: Oral poster abstracts Source Type: research

Canagliflozin Inhibits Human Endothelial Cell Proliferation and Tube Formation
In conclusion, the present study identified canagliflozin as a potent inhibitor of human EC proliferation. The anti-proliferative action of canagliflozin is observed in ECs isolated from both the venous and arterial circulation, and is partly due to the blockade of cyclin A expression. In addition, this study found that canagliflozin inhibits tube formation in cultured ECs and mouse aortic rings. Notably, these actions are specific for canagliflozin and not seen with other SGLT2 inhibitors. The ability of canagliflozin to exert these pleiotropic effects on EC function may contribute to both the adverse and salutary actions...
Source: Frontiers in Pharmacology - April 15, 2019 Category: Drugs & Pharmacology Source Type: research

Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial
Publication date: Available online 25 August 2018Source: The LancetAuthor(s): Marco Valgimigli, Enrico Frigoli, Sergio Leonardi, Pascal Vranckx, Martina Rothenbühler, Matteo Tebaldi, Ferdinando Varbella, Paolo Calabrò, Stefano Garducci, Paolo Rubartelli, Carlo Briguori, Giuseppe Andó, Maurizio Ferrario, Ugo Limbruno, Roberto Garbo, Paolo Sganzerla, Filippo Russo, Marco Nazzaro, Alessandro Lupi, Bernardo CorteseSummaryBackgroundThe Minimizing Adverse Haemorrhagic Events by Transradial Access Site and Systemic Implementation of Angiox (MATRIX) programme was designed to assess the comparative safety and effectiveness of ra...
Source: The Lancet - August 25, 2018 Category: General Medicine Source Type: research